AnaptysBio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2014
Net Income	-163.3	-163.62	-128.72	-57.8	-19.93	-97.34	Upgrade
Depreciation & Amortization	2.39	2.38	2.34	2.09	1.62	1.41	Upgrade
Share-Based Compensation	34.48	33.21	27.36	15.35	11.5	12.41	Upgrade
Other Operating Activities	-7.05	7.24	25.44	-5.56	-7.34	14	Upgrade
Operating Cash Flow	-133.49	-120.8	-73.59	-45.92	-14.16	-69.52	Upgrade
Capital Expenditures	-0.66	-0.81	-0.36	-1.35	-0.57	-0.81	Upgrade
Change in Investments	128.63	145.56	-394.49	40.19	95.04	132.24	Upgrade
Investing Cash Flow	127.97	144.75	-394.85	38.84	94.48	131.43	Upgrade
Share Issuance / Repurchase	-17.96	-47.53	11.83	2.55	0.5	3.01	Upgrade
Debt Issued / Paid	-17.35	-11.73	-2.47	0	-1.38	-7.5	Upgrade
Other Financing Activities	-0.04	-0.04	34.66	249.75	-	-	Upgrade
Financing Cash Flow	-35.36	-59.3	44.02	252.3	-0.88	-4.49	Upgrade
Net Cash Flow	-40.87	-35.34	-424.42	245.21	79.44	57.42	Upgrade
Free Cash Flow	-134.14	-121.61	-73.95	-47.27	-14.73	-70.32	Upgrade
Free Cash Flow Margin	-584.20%	-708.79%	-718.88%	-74.83%	-19.63%	-879.03%	Upgrade
Free Cash Flow Per Share	-5.00	-4.52	-2.63	-1.72	-0.54	-2.60	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).